One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Rumors are spreading all over the place.’ Experts fear the cancellation signals a sidelining of science at federal health ...

Two long-planned vaccine meetings — one at the US Centers for Disease Control and another at the US Food and Drug ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

California dedicated $100 to manufacturing insulin for diabetic residents. That effort is taking longer than Gov. Gavin ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...